Big Pharma's blame game isn't working | Pharmacy benefit managers provide solutions to address the opioid crisis | House subcommittee chair officially opposes Part D point-of-sale rebates
ADVERTISEMENT
April 13, 2018
FOLLOW PCMA ON TWITTER  Twitter
PCMA SmartBrief
News for the PBM Industry
SIGN UP ⋅   FORWARD ⋅   ARCHIVE
Featured Story
Big Pharma's blame game isn't working
Drugmakers' "pass the buck" advertising campaigns have failed, writes John Jones, who teaches pharmacy law and ethics, citing perpetually low polling numbers and legislative defeats.
Montgomery Advertiser (Ala.) (tiered subscription model) (4/12) 
LinkedIn Twitter Facebook Google+ Email
Legislative & Regulatory News
House subcommittee chair officially opposes Part D point-of-sale rebates
House Ways and Means health subcommittee chair Peter Roskam, R-Ill., opposes the idea of point-of-sale rebates under Medicare Part D, according to a spokesperson.
InsideHealthPolicy (subscription required) (4/12) 
LinkedIn Twitter Facebook Google+ Email
Ohio judge sets trial date for opioid-drug marketing, distribution cases
US District Judge Dan Polster will hear arguments next March in three lawsuits brought by Ohio municipalities and counties against opioid-drug manufacturers and distributors Purdue Pharma, Johnson & Johnson, Teva Pharmaceutical Industries, Endo, AmerisourceBergen, Cardinal Health and McKesson.
Reuters (4/11) 
LinkedIn Twitter Facebook Google+ Email
Drug price limits to be on S.D. ballots
South Dakota voters will determine whether the state should promulgate a law allowing state programs to pay no more on drugs than the Department of Veterans Affairs does.
Politico Pro (subscription required) (4/19) 
LinkedIn Twitter Facebook Google+ Email
Drug Industry Spotlight
Cancer drugs' benefits fail to keep pace with rising prices, study finds
Cancer drugs' benefits fail to keep pace with rising prices, study finds
(Chris Hondros/Getty Images)
A study published in the Journal of Oncology Practice found no link between the monthly or incremental costs of new cancer drugs and their clinical benefits. The authors looked at 42 clinical trials for medications approved from 2006 to 2015, finding that average monthly costs of new oncology drugs rose to $15,535 in 2015 from $7,103 in 2006, while the difference in cost between new drugs and those they were intended to replace climbed to $161,141 from $30,447.
Reuters (4/12) 
LinkedIn Twitter Facebook Google+ Email
 
Projected price for migraine drugs cost-effective only in some cases
Analysts expect Amgen and Novartis to set the price on a new type of migraine drug at around $8,500, which the Institute for Clinical and Economic Review said may be cost-effective for treating chronic migraines but not episodic migraines. The institute said the price would not be cost-effective for Teva's new drug for either type of migraine.
STAT (tiered subscription model)/Pharmalot (4/12) 
LinkedIn Twitter Facebook Google+ Email
  
  
Ignoring isn't the same as ignorance; you have to work at it.
Margaret Atwood,
writer
LinkedIn Twitter Facebook Google+ Email
  
  
Learn more about PCMA:
Upcoming PCMA Events | PCMA Newsroom
Become a PCMA Affiliate
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 266 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy policy |  Legal Information